Clinical data defining a new standard of care
Proven to Reduce Hospital Costs
A University of Houston study published in the Journal of Clinical Microbiology found that depending on their baseline contamination rate, hospitals can expect to save between $83 and $367 per blood culture following the adoption of Steripath.
Clinically Proven Results
Steripath was exhaustively tested in a prospective, controlled, matched pair study performed by phlebotomists with results published in Clinical Infectious Diseases - with a sustained contamination rate of 0.2% and a 92% reduction in false positive results.
University of Houston College of Pharmacy
Hospitals can save between $83 and $367 per blood culture following the adoption of Steripath.
Study results show a single false positive blood culture event results in an additional $4,739 in hospital costs. The study concluded that the routine implementation of Steripath ISDD in the ED was a cost -beneficial compared to conventional blood culture collection methods. Depending on a facility’s baseline contamination rate (ranging from 2-8 percent), hospitals can expect a cost savings between $83 and $367 per blood culture following adoption of Steripath. These findings support the routine use of ISDD during blood culture collection in the ED as a cost-beneficial strategy to reduce the clinical and economic impact of blood culture contamination in terms of microbiology, pharmacy and wider indirect hospital impact.
University of Nebraska Medical Center
Peer-Reviewed: Use of Steripath showed a 92% reduction in blood culture contamination estimated to save $1.8M per year
Clinical Infectious Diseases journal has published study results from the University of Nebraska Medical Center led by Dr. Mark E. Rupp, Professor and Chief of the UNMC Division of Infectious Diseases and Medical Director of the Department of Infection Control and Epidemiology at Nebraska Medicine, UNMC’s hospital partner. The study validates the performance of the Steripath blood collection system to reduce blood culture contamination to 0.2% (P=0.001). This represented a 92% reduction compared to a pre-intervention rate of 2.6% and 88% reduction compared to the phlebotomist control group intervention rate of 1.8%. Post hoc analysis found contamination rates increased 12 fold to 2.8% without the use of Steripath. Researcher calculated the study institution would save $1.8M per year with Steripath
Peer-Reviewed: An 83% reduction in blood culture contamination with the use of Steripath in a multi-center controlled clinical study
The study results show that the Steripath blood culture collection and contamination prevention system reduced blood culture contamination to a sustained 0.6% (P=0.0001) across 4 Emergency Departments over a 7-month period. This represented a 82.8% reduction compared to a pre-intervention rate of 3.52%. Post hoc analysis found that BCC rate reduction was comparable across all 4 facilities, with each Emergency Department achieving a sustained sub-0.75% rate of contamination after adoption of the device. During the observational period of this study, projected cost savings exceeds $641,000 and prevented approximately 184 patients from being exposed to the risks associated with a false positive blood culture.
Rush University Medical Center
Study shows an 86% reduction in blood culture contamination with use of Steripath ISDD
Prospective study results showing an 86% reduction in blood culture contamination, 4.3% when using standard aseptic technique vs. 0.6% utilizing Steripath. Steripath represents a simple and effective method for reducing blood culture contamination.
San Antonio Military Medical Center
Use of Steripath showed a 92% reduction in blood culture contamination estimated to save $235,000 in less than five months
The study results show a 92% reduction in blood culture contamination, 7.7% using standard collection method vs. 0.6% utilizing Steripath, and a projected costs savings of $235,000 in five months.
San Antonio Military Medical Center
A 37% decrease in Vancomycin days of therapy attributed to use of the Steripath device
Retrospective study results showing a 37% decrease in Vancomycin days of therapy attributed to Steripath.
Steripath use resulted in a sustained 0.76% contamination rate in the ED, leading to hospital-wide adoption
Prospective study results showing an 75% reduction in blood culture contamination, 3.0% when using standard collection method vs. 0.8% utilizing Steripath. Results led the hospital to adopt Steripath as standard practice hospital-wide.
Medical University of South Carolina
Steripath resulted in a sustained blood culture contamination rate below 0.9% for 20 months
Prospective study results show Steripath drove a nearly four-fold reduction in false-positive blood culture rate compared to the non-Steripath rate during the same time period. Estimated cost savings to the institution of $744,955 for the study period if there were 100% compliance. Compliance rate impacted by uncooperative or "difficult to stick" patients.
Medical University of South Carolina
Use of Steripath proved an 86% reduction in blood culture contamination driving expansion to an additional ED and ICU
Prospective study results showing an 86% reduction in blood culture contamination, 4.2% when using standard collection method vs. 0.6% utilizing Steripath. Results drove expansion of Steripath use to a second, separate adult ED, and the ICU.
Michael E. DeBakey VA Medical Center - Houston
ER Steripath ISDD use resulted in a 83% decrease in blood culture contamination
Prospective study results showing an 83% reduction in blood culture contamination when using standard collection method vs. utilizing Steripath. The study supported Leadership decision to implement Steripath ISDD hospital-wide.
VA - North Texas Health Care System
Use of Steripath resulted in a 69% reduction in blood culture contamination (blended rate) estimated to save $332,500 over five months
Poster presented as a Green Belt Project 2016, study results showed a post-Steripath adoption blended (combined Steripath and standard method results) blood culture contamination rate of 1.7% at 50% compliance compared to a pre-Steripath implementation of 5.3%, representing a 69% reduction. Steripath enabled a 45% reduction in blood culture collection steps and an estimated savings of $332,500 over a five month period.
Sustained Customer Results
In addition to clinical study environments, Steripath has repeatedly outperformed traditional blood culture collection methods in emergency departments across the nation.
"Implementing Steripath has dramatically decreased our contamination rates, resulting in savings through reduced length of stay and improved patient outcomes across all four campus emergency departments."
Mary B., MSN, RN, CEN, Fort Myers, FL
“[Steripath] has helped us to lower our blood culture contamination rates from above 3% on a monthly basis to below the national benchmark for every succeeding month after our initiation of the device. Magnolia provided great resources and training for the system which definitely aided in our success. The majority of the staff like the device and find it rather easy to use after the proper training. We are going to continue to use the device and ride along with Magnolia through this journey of success!”
Jessica P., MSN, RN, CEN, Cape Coral, FL
"The bottom line is that when a culture was drawn without the device (Steripath), we made no progress at all in our contamination rates. The average at the end of 16-weeks was 3%, actually up slightly from where we started. But when the device (Steripath) was used, the contamination rate was 0.7%, which is a 77% improvement in the contamination rate. That is really meaningful progress, and I thank everyone for making it happen!"
Jennifer Blakeney, MT(ASCP)SM, Lead Technologist Microbiology/Immunology, Beebe Healthcare
The evidence speaks for itself.
Let us share more.